KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Restructuring Costs (2024 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Restructuring Costs for 2 consecutive years, with $8.5 million as the latest value for Q4 2025.

  • Quarterly Restructuring Costs rose 53.99% to $8.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $26.8 million through Dec 2025, up 29.71% year-over-year, with the annual reading at $26.8 million for FY2025, 29.71% up from the prior year.
  • Restructuring Costs for Q4 2025 was $8.5 million at Xenon Pharmaceuticals, up from $6.7 million in the prior quarter.
  • The five-year high for Restructuring Costs was $8.5 million in Q4 2025, with the low at $4.6 million in Q3 2024.